Company: MDXG
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001376339-25-000048
Chunk: 67

Company: MIMEDX GROUP, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 67
---
 However, Adjusted EBITDA grew substantially in 2023 as described above, and our executive compensation increased in parallel. In 2024, we continued to deliver a healthy improvement in our Adjusted EBITDA as stronger sales growth and continued expense management resulted in a year-over-year improvement in this profitability metric.

R&D Goals – The Company also set several R&D goals for the business in order to continue to bring new products to the market. In late 2022, we were able to successfully launch two such products for our Wound & Surgical business, and in 2023 and 2024, we also introduced new products to continue our portfolio expansion. We continue to invest in R&D activities with the aim of continuing to innovate, resulting in the launches of additional products in future periods.

Our net income and loss variations from 2020 to 2022 were more reflections of the end of FDA enforcement discretion and other factors, and therefore had less impact on our executive compensation actually paid. However, net income grew in 2023 as described above, and our executive compensation increased in parallel. In 2024, our net income declined sequentially, primarily due to a one-time tax benefit recognized in 2023, which did not recur in 2024. Excluding this one time impact, our net income in 2024 remained very healthy, particularly compared to prior years.

### EQUITY COMPENSATION PLAN INFORMATION
The following table provides information about the Company’s equity compensation plans as of December 31, 2024.

<div align='center'>40</div>

| Plan Category                                               |     | Number of securities to be issued upon exercise of outstanding options, warrants and rights |     |         |     | Weighted average exercise price of outstanding options, warrants and rights |       |     | Number of securities remaining available for future issuance under equity compensation plans |     |           |
|:------------------------------------------------------------|:----|:--------------------------------------------------------------------------------------------|:----|--------:|:----|:----------------------------------------------------------------------------|------:|:----|:---------------------------------------------------------------------------------------------|:----|----------:|
| Equity compensation plans approved by security holders1     |     |                                                                                             |     |  17,500 |     | $                                                                           | 10.03 |     |                                                                                              |     | 9,569,352 |
| Equity compensation plans not approved by security holders2 |     |                                                                                             |     | 323,500 |     |                                                                             |  3.90 |     |                                                                                              |